on ABIONYX (EPA:ABNX)
ABIONYX Pharma: Third quarter 2024 financial report
ABIONYX Pharma, a biotechnology company specializing in the development of innovative therapies, reported consolidated revenue of €3.41 million for the third quarter of 2024. This result comes entirely from its subsidiary IRIS Pharma, as no other studies were entrusted to it during this period.
Regarding finances, the company posted cash of 4.1 million euros as of September 30, 2024, before the expected reimbursement of the Iris Pharma Research Tax Credit estimated at 610,000 euros.
The combined general meeting of ABIONYX will be held on November 28, 2024. Key topics include the appointment of new directors and resolutions for future development and shareholder loyalty in line with the law of June 13, 2024.
R. E.
Copyright © 2024 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all ABIONYX news